It's not often that you see a developmental-stage biotech company's stock go up after it gets dropped by its pharma big brother, but Alnylam Pharmaceuticals
Alnylam and Merck
The collaboration has been in turmoil since Merck bought Alnylam's rival, Sirna Therapeutics, last year. The purchase meant that Merck no longer needed much of the expertise that Alnylam brought to the table. Alnylam's partner was now also a rival, so helping out Merck might have resulted in competition in drugs developed outside the partnership.
The only real question is why the two didn't end the partnership months ago. While the dissolution of the partnership results in a loss of funding for Alnylam, it's not like the company has been left to go it alone. It still has partnerships with Medtronic
The phase 2 clinical trial results from Alnylam's lead compound, ALN-RSV01, are due in later this year. If they are positive, Alnylam could score an additional partnership. But with an expected $435 million in cash at the end of this year, Alnylam could try to push into phase 3 clinical trials alone, especially if it can score a few more of those non-exclusive technology licenses like the one it has with Roche.
More from The Motley Fool
Will 2018 Be Alnylam Pharmaceuticals, Inc.'s Best Year Yet?
There's a lot of good news potentially on the way for the biotech. But its 2017 performance will be hard to beat.
This Is Why Alnylam Pharmaceuticals Soared 249% in 2017
It was a breakout year for the clinical-stage biotech.
Alnylam Gets Some Welcome News
A trial that had been on clinical hold because of a patient death has been cleared to restart.